With so many 50-and-older adults having already received the first of a two-part vaccination, there's simply not enough of the medicine, called Shingrix, to go around. Instead of getting their second shot to complete the series, what many have received instead is a spot on a waiting list. But the manufacturer of the promising anti-shingles vaccine says it's ramping up production to meet "unprecedented” demand.
With so many 50-and-older adults having already received the first of a two-part vaccination, there's simply not enough of the medicine, called Shingrix, to go around. Instead of getting their second shot to complete the series, what many have received instead is a spot on a waiting list. But the manufacturer of the promising anti-shingles vaccine says it's ramping up production to meet "unprecedented” demand.